Moderna announced on the 7th (local time) that it has started a phase 1/2 trial of “mRNA-1010”, a candidate for the mRNA vaccine for seasonal influenza. A clinical trial in healthy adults over the age of 18 will verify the safety, responsiveness, and immunogenicity of mRNA-1010. Seasonal influenza (types A and B) causes respiratory illness and places a heavy burden on the medical system. According to the WHO, the death toll from respiratory illnesses that may be associated with the flu is estimated to be around 290,000 to 650,000, and the average financial burden in the United States is projected to reach about $ 11 billion annually. is there. The effectiveness of existing influenza vaccines is only around 40-60%, and the production is egg-based, which can cause unintended changes in antigenicity. On the other hand, the mRNA vaccine is expected to have the function of protecting against multiple viruses by combining different antigens (combination vaccine), and to respond quickly to the evolution of viruses such as influenza, SARS-CoV-2, and RS virus. There is.